Written by Agnese Cattaneo, Chief Medical Officer, Angelini Pharma

Innovation plays a key role in the healthcare environment, an area in which Angelini Ventures, the venture capital firm of Angelini Industries, plays an active role by investing in and supporting cutting-edge startups in the biotechnology and digital health sectors. Angelini Ventures focuses its investments in five strategic segments: Biotech, TechBio, Connected Health Devices, Digital Diagnostics & Therapeutics, and Hybrid Care Platforms. The goal is to catalyze progress in crucial areas of health, starting with the understanding that curing means networking.

The transition from the concept of "new normal" to "polycrisis" has occurred in a surprisingly short span of time. This rapid transition highlights how global society has gone from adapting to a new post-pandemic status quo to dealing with a complexity of simultaneous and interconnected crises in record time. Faced with this scenario, the question arises: how can governments, organizations and individuals respond effectively to this "age of polycrisis"?

Angelini Ventures' approach to venture capital is distinguished by its unique business model, which seeks to create growth opportunities for the Angelini Industries group by creating access to innovative companies in the world of healthcare and new markets with high development potential without limiting itself exclusively to the concept of financial investment. An interview to the CEO, Paolo Di Giorgio.

There are many factors affecting mental health, including climate change, conflict and migration. This is what emerges from "A new roadmap in Mental Health": a Headway report resulting from a collaboration between The European House - Ambrosetti, an Italian Think Tank, and Angelini Pharma.